Targeting Labile Iron-Mediated Ferroptosis Provides a Potential Therapeutic Strategy for Rhabdomyolysis-Induced Acute Kidney Injury
ACS Chemical Biology · 16.06.2023 · 18 (6) · 1294-1304
DOI: 10.1021/acschembio.2c00914 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 12.05.2023. Verfasst von Haiying Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang…. Hauptthemen laut MEDLINE: Ferroptosis, Acute Kidney Injury, Rhabdomyolysis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Basic Public Welfare Research Program of Zhejiang Province, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Acute kidney injury (AKI) is a global health problem that occurs in a variety of clinical settings. Despite some advances in supportive clinical care, no medicinal intervention has been demonstrated to reliably prevent AKI thus far. Therefore, it is highly necessary to investigate the pathophysiology and mechanisms involved in AKI for the discovery of therapeutics. In the current study, a robust change in the level of renal malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) and elevated renal iron levels were observed in murine rhabdomyolysis-induced AKI (RM-AKI), which supports a pathogenic role of labile iron-mediated ferroptosis and provides a chance to utilize iron chelation for RM-AKI prevention. Given that the existing small molecule-based iron chelators did not show promising preventative effects against RM-AKI, we further designed and synthesized a new hydroxypyridinone-based iron chelator to potently inhibit labile iron-mediated ferroptosis. Lead compound AKI-02 was identified, which remarkably protected renal proximal tubular epithelial cells from ferroptosis as well as showed excellent iron chelation ability. Moreover, administration of AKI-02 led to renal function recovery, a result that was substantiated by the decreased contents of BUN and creatinine, as well as the reduced labile iron level and improved histopathology. Thus, our studies highlighted that targeting labile iron-mediated ferroptosis could provide therapeutic benefits against RM-AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China.
- Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, Hangzhou 310058, China.
- Cancer Center, Zhejiang University, Hangzhou 310058, China.
ORCID-Profile: Yongping Yu, Wenteng Chen
Förderung
- Basic Public Welfare Research Program of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhu, H., Cen, J., Hong, C., Wang, H., Wen, Y., He, Q., Yu, Y., Cao, J., & Chen, W. (2023). Targeting Labile Iron-Mediated Ferroptosis Provides a Potential Therapeutic Strategy for Rhabdomyolysis-Induced Acute Kidney Injury. ACS Chemical Biology, 18(6), 1294-1304. https://doi.org/10.1021/acschembio.2c00914
Vancouver
Zhu H, Cen J, Hong C, Wang H, Wen Y, He Q, et al. Targeting Labile Iron-Mediated Ferroptosis Provides a Potential Therapeutic Strategy for Rhabdomyolysis-Induced Acute Kidney Injury. ACS Chemical Biology. 2023;18(6):1294-1304. doi:10.1021/acschembio.2c00914
BibTeX
@article{Zhu2023,
author = {Zhu, Haiying and Cen, Jie and Hong, Chenggang and Wang, Haiyang and Wen, Yuanmei and He, Qiaojun and Yu, Yongping and Cao, Ji and Chen, Wenteng},
title = {Targeting Labile Iron-Mediated Ferroptosis Provides a Potential Therapeutic Strategy for Rhabdomyolysis-Induced Acute Kidney Injury},
journal = {ACS Chemical Biology},
year = {2023},
volume = {18},
number = {6},
pages = {1294--1304},
doi = {10.1021/acschembio.2c00914}
}
EUVIMED